Top 50 Biotech Angel Investors in United Kingdom in May 2026
Top 50 Biotech Angel Investors in United Kingdom in May 2026
| Investor | Biotech United Kingdom investments |
|---|---|
| Jonathan Milner | 30 |
| Nadav Rosenberg | 5 |
| Jeff Dean | 3 |
| Paul Wicks | 3 |
| Bradley Horowitz | 3 |
| Milad Alucozai | 3 |
| Ian Hogarth | 3 |
| Peder Nielsen | 3 |
| Charlie Songhurst | 3 |
| Jude Gomila | 3 |
| Darrin Disley | 3 |
| Stefano Bernardi | 3 |
| DrPano Kroko Churchill | 3 |
| Paul Forster | 2 |
| Tim Dempsey | 2 |
| Chris Mairs | 2 |
| Ed Parkinson | 2 |
| Edward Lando | 2 |
| Aidan Gomez | 2 |
| Mark Evans | 2 |
| Inaki Berenguer | 2 |
| Gilad Engel | 2 |
| Jon Oringer | 2 |
| Jim Mellon | 2 |
| Hugh Grant | 2 |
| Ariel Poler | 2 |
| Nick Boyle | 2 |
| Mati Staniszewski | 2 |
| Patrick Pichette | 2 |
| Robert Kopple | 2 |
| Damien Lane | 2 |
| Jon Oringer | 2 |
| Serge Chiaramonte | 2 |
| Pratima Aiyagari | 2 |
| Jon Oringer | 2 |
| Nadav Ben-Chanoch | 2 |
| John Anthony Knight | 1 |
| Jon Moulton | 1 |
| Mark McCamish | 1 |
| Hugo Amsellem | 1 |
| Rick Bernstein | 1 |
| Alex Payne | 1 |
| Sharaf Yamani | 1 |
| Christine Soden | 1 |
| Sarah Howell | 1 |
| Sami Mikati | 1 |
| Oliver Sexton | 1 |
| Jim Warwick | 1 |
| Siddhant Jayakumar | 1 |
| Andrew J M Richards | 1 |
Reach every investor
Get a list of investors who already back your industry, stage, and country. Emails & phones included.
Find investors — It's Free!Having worked in the life sciences industry for over ten years as an academic researcher, Jonathan identified the market opportunity for supplying high quality antibodies to support protein interaction studies and, in 1998, founded Abcam with David Cleevely and Professor Tony Kouzarides. Jonathan is a Non-Executive Director of Horizon DiscoveryGroup plc, The Evolution Education Trust, GeoSpock Ltd and Sydicate Room Group Ltd. He is also Chairman of Axol Bioscience Ltd, PhoreMost Ltd, Repositive Limited, Definigen Limited and Cambridge Allergy Ltd. Jonathan holds an executive director position at Meltwind Limited, being a designated member of Meltwind Advisory LLP. Jonathan is an experienced entrepreneur and investor and is passionate about supporting UK life science and high-tech start-ups. He has provided considerable investment and support to over 30 companies and has assisted three AIM IPOs.
Show more...Investment focus
- Biotechnology, Health Care, Medical
- Seed, Series A, Series B
- United Kingdom, United States, Spain
Portfolio highlights
- Nuclera — Nuclera makes biology accessible through desktop enzymatic protein and gene synthesis. Nuclera has since grown to fifty-seven employees across two continents as the Company delivers on its founders’ vision to make biology accessible to everyone through desktop bioprinting. With desktop bioprinting, researchers and scientists will be empowered totake control of biology through streamlined access to a next-day supply of proteins and genes.
- 52 North Health — At 52 North we are developing fully-integrated clinical, AI and medical-device based systems.
- Constructive Bio — We place non-canonical amino acids at precise positions in proteins and peptides to create therapeutics with new properties, then manufacture them through fermentation.
Nadav leads Taboola’s expansion and operations in Europe and Australia.Prior to joining Taboola, Nadav was a member of the founding team of Groupon UK & IR, taking part in building and managing Groupon’s business in the UK.Before joining Groupon, Nadav worked as a strategy consultant with McKinsey & Company in London.Nadav isbased in London and holds an MBA from INSEAD, France.
Show more...Investment focus
- Biotechnology, Artificial Intelligence, Software
- Seed, Pre-Seed, Series A
- United Kingdom, France, Israel
Portfolio highlights
- Qantev — Qantev is the leading AI claims platform for health & life insurance, enabling insurers to automate claims operations, reduce leakage, improve loss ratios, enhance data quality, and elevate customer experience.
- thymia — We use video games based on Neuropsychology alongside analyses of video and speech to make mental health assessments smart, starting with depression.Our online platform empowers clinicians so they can assess depression faster, more accurately and objectively. Our multi-modal depression recognition and tracking system allows us to find the righttreatment in weeks instead of years and we make the entire process enjoyable for the patient.
- Exogene — Exogene is a biotechnology company accelerating the discovery of T-cell-receptor(TCR)-based cancer immunotherapies for solid tumours by combining deep learning and high-throughput TCR-antigen screening. Exogene is building a computational platform to quickly and inexpensively identify new tumour targets shared across cancer patients, as well assafe and effective TCRs against these tumour targets for therapeutic application. Their mission is to develop better TCR-based immunotherapies, faster and at a fraction of the cost.
Jeff Dean is the Chief Scientist of Google DeepMind and Google Research. He joined Google in 1999 and has played a pivotal role in shaping the company’s technical foundations. He currently focuses on advancing AI and deep learning research across Google’s research teams.He co-founded and led the Google Brain team, helping drive innovations indeep learning for speech recognition, computer vision, natural language understanding, and a wide range of predictive applications. Over the years, he has co-designed and implemented several generations of Google's core systems, including its web search infrastructure, crawling and indexing pipelines, and advertising technologies such as AdSense for Content.He is also a key contributor to Google's distributed computing infrastructure, having co-designed and implemented systems like MapReduce, BigTable, Spanner, Protocol Buffers, LevelDB, and TensorFlow—one of the most widely used open-source machine learning platforms.Jeff Dean earned his Ph.D. in Computer Science from the University of Washington in 1996. He is a Fellow of the ACM, a member of the U.S. National Academy of Engineering and the American Academy of Arts and Sciences, and a recipient of the ACM-Infosys Foundation Award in the Computing Sciences and the Mark Weiser Award.
Show more...Investment focus
- Artificial Intelligence, Information Technology, Software
- Seed, Series A, Pre-Seed
- United States, United Kingdom, Japan
Portfolio highlights
- RunSybil — RunSybil is an AI-driven offensive security platform that continuously evaluates applications and infrastructure for vulnerabilities. Leveraging cutting-edge AI techniques, it autonomously identifies and exploits real-world security flaws through sophisticated penetration testing. By automating hacker-like intuition, RunSybil delivers proactivedefense capabilities, empowering organizations to strengthen the security of modern applications.
- Meshcapade — Foundation models that teach AI to see, understand, and move.
- Supermemory — Supermemory offers a platform for organizing and retrieving saved knowledge through a combination of memory APIs, semantic search, and integrated tools. It enables users and developers to import content from documents, bookmarks, and external services, and then query that content using natural language. Supermemory supports workflows like building“second brain” systems, intelligent agents, and knowledge bases by connecting context across documents. It provides permission controls and integration with large language models to allow applications to maintain stateful, evolving memory. Supermemory also addresses use-cases in research, content writing, support systems, and enterprise knowledge management.
Paul Wicks, Ph.D., is a strategic advisor and independent consultant who helps digital health and life science companies turn data into evidence, evidence into influence, and influence into impact. He has supported over 40 organizations including AstraZeneca, Ada Health, Biogen, Click Therapeutics, and Woebot.Previously, Paul spent 13 years as VPof R&D at PatientsLikeMe, building one of the world’s largest patient communities and pioneering decentralized trials, digital biomarkers, and real-world evidence. He has authored over 200 peer-reviewed papers and served on editorial boards of journals including the BMJ, Digital Biomarkers, and BMC Medicine.A neuropsychologist by training, Paul completed his Ph.D. at King’s College London and a postdoc on the psychology of Parkinson’s disease. His work has been featured by BBC, CNN, and The New York Times. He was named MIT Technology Review’s “Humanitarian of the Year” in 2011 and is a TED Fellow and FLIER alumnus of the Academy of Medical Sciences. He is an honorary Professor at the University of Birmingham.
Show more...Investment focus
- Software, Wellness, E-Commerce
- Seed, Pre-Seed, Series A
- United Kingdom, United States, Japan
Portfolio highlights
- Epiminds — Epiminds develops multi-agent AI systems to run marketing end-to-end.
- Run Yourself — RunYourself is a prompt-driven, AI-assisted platform making it easy for managers to have effective coaching conversations. We blend expert coaching prompts on a spectrum of crucial topics with AI-powered support. This enables managers to have productive peer coaching conversations with other managers and more effective coaching, feedback, performance and career development conversations with their team members.
- MakeSense Technology — MakeSense is a team of tech experts, empowering people who are blind or have low vision.
Bradley Horowitz is an Advisor and Vice President of Product Management at Google. Most recently he helped create Area 120, Google's incubator for internally-sourced innovation. He's led a large number of products, programs and initiatives at Google - including Google for Startups, Google Photos, Gmail, Google Voice, blogger, and GoogleNews.Before joining Google in February 2008, Horowitz was Yahoo's vice president of Advanced Development where he drove the acquisitions of Flickr and MyBlogLog, launched the Brickhouse incubator and developed new products like Yahoo! Pipes. Additionally, he was responsible for the company's initiative to open up its platform which included overseeing the Yahoo Developer Network (YDN).Previously, he was co-founder and CTO of Virage, where he oversaw the technical direction of the company from its founding through its IPO and eventual acquisition by Autonomy.Horowitz was a PhD candidate at the MIT Media Lab. While at the Media Lab, he worked on a number of topics related to computer vision, graphics and image processing, which resulted in a patented new technique for the recovery of structure, motion and camera parameters from video sequences.Horowitz holds an MS in Media Science from MIT and a BS in Computer Science from the University of Michigan.
Show more...Investment focus
- Software, Information Technology, Health Care
- Seed, Series A, Series B
- United States, United Kingdom, Germany
Portfolio highlights
- Key AI — Unlock new networking and career opportunities with Key, the leading AI-powered professional networking platform. Build and manage communities, host and join exclusive events, and create meaningful connections to supercharge your growth all in one place.
- Opal — Making it better at capturing incredible low-light video. Even in dimly lit room, you’ll get a level of detail and color that wasn’t possible before.The Opal C1 comes with MicMesh™, an array of beamforming microphones that find and focus on the sound of your voice. And with intelligent noise cancellation, every ding, drop and dog bark is filteredout to get an audio experience that clearly speaks for itself.
- Audioshake — AudioShake makes audio interactive, customizable, and accessible by using AI to separate sound recordings into their component parts and stems.
Recognized by Business Insider in 2025 as “one of the top 100 early-stage investors,” Dr. Alucozai has experience translating exceptional science and technology into scalable commercial ventures. Alongside his experience as a founder and operator, he has actively invested in over 100 startups across North America and Europe. He has often been thefirst investor to back high-growth companies like Seqera Labs. Milad began his career as a neuroscientist at the intersection of bioengineering, computational biology, and machine learning, where he commercialized platforms designed to deliver promising medicines to patients more efficiently and safely. His focus as an investor has been to accelerate the journey of groundbreaking discoveries from the lab to the market, particularly in the life sciences sector and related computational fields.Milad is a co-founder and General Partner at Pamir Ventures, an early-stage venture firm that invests in technical pioneers developing B2B companies utilizing AI in antiquated industries. He is also a co-founder of Revalia Bio, which aims to establish a human-centric infrastructure for drug discovery and development. By using non-transplantable human organs donated for research, Revalia offers the scientific community unparalleled insights into patient biology, ultimately aiding in the creation of improved treatments and cures. Throughout his operating and investing career, Milad has played a crucial role in helping founders secure hundreds of millions in capital and facilitating over $1 billion in startup-pharma partnerships. His previous roles include supporting business development at Accenture, Absci, Bit Bio, Numerate, Mekonos, and AstraZeneca. Through Digitalis Commons, he was an Expert in Residence in support of the Advanced Research Projects Agency for Health (ARPA-H), where he aided the US government and ARPA-H mission to enable transformative biomedical and health breakthroughs, providing health solutions through $1.5 billion in non-dilutive investments. He was a National Science Foundation Scholar and Macklin Fellow at Johns Hopkins Medicine. He graduated Phi Beta Kappa with a degree in Neuroscience from Purdue University’s Honors Program, earned a master’s in Immunology and Public Health as a George J. Mitchell Scholar, and holds a doctorate from the Richard M. Fairbanks School of Public Health. Additionally, he completed a Visiting Scholar appointment at the Wyss Institute at Harvard University.
Show more...Investment focus
- Biotechnology, Health Care, Medical
- Seed, Series A, Pre-Seed
- United States, Canada, United Kingdom
Portfolio highlights
- Replit — Replit is a simple yet powerful online IDE, Editor, Compiler, Interpreter, and REPL. Code, compile, run, and host in 50+ programming languages.
- Future Fields — Future Fields Cellular Agriculture: Serum-Free Growth Media Supplements and Recombinant Proteins - Optimized for the Future of Food.
- Endpoint Health — Endpoint Health is a precision-first therapeutics company. By rewriting the molecule-first drug development model, we aim to deliver precision therapies that have the potential to improve outcomes for patients with immune-driven illnesses.
Ian got a master's in machine learning at Cambridge and loves dystopian robot takeover narratives. Seven years ago, Ian realized being a choirboy came with no street cred, so he started DJing hip-hop, funk, drum & bass, and grime. Ian quit his job at Bain & Company, Singapore to start Songkick.
Show more...Investment focus
- Software, E-Commerce, Medical
- Seed, Pre-Seed, Series A
- United Kingdom, United States, Germany
Portfolio highlights
- Claimer — Claimer is a self-service application that gets credit claims done easily of money spent on research and development. Its platform empowers company owners and advisors to prepare their claims, without any specialist knowledge, no matter how big or small the claim. It also prepares and submits the amended tax return for free.Claimer was founded in2019 by Adam McCann and is headquartered in Croydon, United Kingdom.
- Unitary — We detect harmful content with context-aware AI to keep brands and platforms safe online.
- Fabric — Fabric is an AI-powered workspace and file manager for people and groups.Fabric is a self-organizing multiplayer workspace.
Peder Nielsen - Member of the Global Advisors Network @ Global Bio Fund
Show more...Investment focus
- Biotechnology, Machine Learning
- Seed, Funding Round, Convertible Note
- United Kingdom
Portfolio highlights
- Bactobio — At Bactobio, our mission is to create a safer and greener world by harvesting valuable metabolites from biological dark matter.
Charles Songhurst is a founding partner of Katana Capital, a long-short equity hedge fund. He also runs the Songhurst Group, which holds assets in a variety of private companies.Charles ran corporate strategy for Microsoft and focused on partnering and M&A. He was involved in the Yahoo acquisition and commercial deal, and the Skypeacquisition. Before running corporate strategy, Charles was focused on the emergence of Google and the growth of the search industry.Prior, Charles was an analyst at McKinsey & Company in London. Charles received a bachelor’s degree from Oxford University in politics, philosophy, and economics.
Show more...Investment focus
- Software, Information Technology, Artificial Intelligence
- Seed, Pre-Seed, Funding Round
- United Kingdom, United States, Germany
Portfolio highlights
- Nexcade — Bringing intelligent automation to Freight Forwarding. Nexcade builds agents that meet forwarders where they work today- cutting through noise, accelerating descisions, and helping teams win more business.
- Forgent AI — Forgent uses AI agents to draft tender proposals, find opportunities and coordinate teams.
- Interface — Interface is an AI-native Document Management System for High Hazard Industries.
Jude Gomila is currently CEO and Founder of the startup Golden.
Show more...Investment focus
- Software, Biotechnology, Information Technology
- Seed, Pre-Seed, Angel
- United States, United Kingdom, Canada
Portfolio highlights
- HockeyStack — HockeyStack enables marketing teams to drive pipeline efficiently and sales teams to close deals faster with modern attribution, holistic buyer journeys, and account insights.
- Farmako — Install Farmako app, get a free health ID and get all your medical records safe and secure in one place!
- Athens Research — Open-Source Roam Research. A private, extensible, and community-driven knowledge graph.
Darrin Disley is the CEO, Director & Investor at Mogrify. He attended University of Cambridge.
Show more...Investment focus
- Biotechnology, Health Care, Big Data
- Seed, Series A, Funding Round
- United Kingdom
Portfolio highlights
- bit.bio — Bit.bio specializes in the fields of coding and biology that determine the identity of every human cell. Their mission is coding cells for health. To do so, we apply the principles of computation to biology. Bit.bio's current focus is to develop a scalable technology platform capable of producing consistent batches of every human cell. Thishas the potential to unlock a new generation of medicine: it will enable research and drug discovery to move on from inappropriate models and work with the cells that actually are affected by the human disease. A scalable platform of consistent cells will also be the basis for a new generation of cell and tissue therapies. To achieve our goals, we have assembled a team of pioneers in stem cells, cellular reprogramming, mathematical modeling, and cell therapy. Collaboration is at the heart of bit.bio. We are empirical, highly ambitious, and driven by a common purpose.
- Mogrify — Mogrify is pioneering a new class of in vivo reprogramming therapy and transforming the development of ex vivo cell therapy.
- Desktop Genetics — Desktop Genetics is an international biotechnology company established in 2012 to help researchers discover and treat the root genetic causes of human disease. Today, Desktop Genetics is a recognised leader in genome editing technology, staffed by dedicated team of genome editing experts, bioinformaticians and data scientists, driven by thereal-world impact of CRISPR technology.They have invested four years developing their core technology, DESKGEN AI, trained on the largest database of genome editing data in the world. DESKGEN AI powers their flagship DESKGEN CRISPR Library product range, which enables the work of their pharma, biotech and academic customers working in drug discovery and functional genomics. Desktop Genetics' tools and technologies are used by over 1800 organisations all over the world, and their projects contribute directly to several key partnerships to bring CRISPR into the clinic. The company has received awards from Fast Company, Kairos 50 and SxSW Interactive.
Stefano Bernardi is the Investment Director, Climate at Fondazione ENEA Tech.
Show more...Investment focus
- Software, Biotechnology, CleanTech
- Seed, Pre-Seed, Funding Round
- Italy, United Kingdom, France
Portfolio highlights
- Eden Bio — Eden Bio is a biotech using machine learning to guide the genetic engineering of microorganism strain optimisation, improving protein yield.
- Golden — Golden is a developer of a self-constructing knowledge database used to accelerate discovery and education. The company uses and leverages human effort by using machine intelligence to make the process of gathering and communicating knowledge simpler.It combines a powerful search across several entities with fine-grain alerts to stay on top ofchanges, and semi-automatic research assistance for gaps in knowledge that enable people in organizations to stay current, understand and leverage the latest trends in their industry.
- Kresko Labs — Join the Quest for accessible wealth with Kresko, a synthetic asset protocol. Explore innovative possibilities now.
Pano Kroko is a legendary entrepreneur, Angel, VC and PE investor in innovation towards solving big problems. His investment emphasis is on Life Sciences, Biotech, Therapeutics, Medicine, Internet, Mobile, Communications, Clean Technology, Renewable Energy, and Environmental Finance. We have a quarterly Business Plan competition for placementin our early stage start up accelerator in Seattle Washington. We also run a program in Washington DC, and we have an Innovation Master Class Startup Weekend that runs Ten times a year in Seattle, Beijing, Silicon Valley, and in major Universities around the world.The Accelerator in Seattle & Silicon Valley is called American Angels, and the Accelerator in Washington DC is named H2O and both accept business plans and great ideas with Founders, and Executive teams right now. We would like to see StartUps in all of our areas of focus as well as anything else that is great and promising to solve Big Problems. Parallel to this we also run the CEP - Clean Energy Program incubator in Oxford UK, and the Biotech accelerator for genetics, stem cell applications, genomics, medicine, pharma and telomeres research in Cambridge UK.For our more traditional VC and PE work in the US, the American Venture Company in the US and the Investment Bank Green Capital Inc in the UK and Europe. These are our conduits of support for companies and also the Green Bonds Investments Plc. All of our organizations act as levers of positive change for impact investing, and as corporate environmental investment responsibility -- within the Finance community.In Seattle and in Silicon Valley we run the Accelerator and Early Stage Investment firm AMERICAN ANGELS where we have monthly pitches and demos for new StartUps and we also run a CEO roundtable to help promising Entrepreneurial leaders to succeed.If you or your company is interested in cooperation, presenting, funding, deal syndication or simply for submission of Executive Summaries and Business Plans for early stage angel funding and/or inclusion in the H2O Incubator/Accelerator or the Clean Energy program and the Biotech incubator, please contact us herewith: Mr Ruddy Wallace: envpar [at] gmail.com
Show more...Investment focus
- Health Care, Therapeutics, Biotechnology
- Angel, Series A
- United Kingdom
Portfolio highlights
- Amrit Advanced Biotech — Company working in Genetics, Telomeres health applications, cancer mitigation and lengthening of....
Paul Forster
Show more...Investment focus
- Software, FinTech, Financial Services
- Seed, Series A, Pre-Seed
- United Kingdom, Germany, United States
Portfolio highlights
- Habito — We're the Treating Customers Fairly Champion of 2023 as voted for in the British Bank Awards. We're here to make mortgages easier - no paperwork, no stress and no fees.
- Kombo — One unified API for HRIS, Payroll & ATS
- Bounti — Bounti helps organizations steer, enable, and scale their frontline employees, combining training, quality control, communication, and operations execution into one intuitive app. With Bounti, companies can maintain consistent quality and operations, streamline training and reach their entire workforce in more than 100 languages.
Tim Dempsey is a Managing Partner at Epiphany Capital. He graduated from the University of Manchester.
Show more...Investment focus
- Software, SaaS, Financial Services
- Seed, Series A, Funding Round
- United Kingdom
Portfolio highlights
- Lunio — Say goodbye to wasted ad spend and false conversions. Use Lunio to stave off click fraud and invalid users, safeguarding the quality of your traffic and driving better returns from paid media
- Mitra bio — We are transforming skin-care by approaching ageing as a disease to be fought. We are developing a genetic and epigenetic discovery platform to help skincare companies find and develop new compounds that actually fight the root cause of skin ageing.
- PPC Protect — Say goodbye to wasted ad spend and false conversions. Use Lunio to stave off click fraud and invalid users, safeguarding the quality of your traffic and driving better returns from paid media
Chris Mairs - Venture Partner @ Entrepreneurs First
Show more...Investment focus
- Software, FinTech, Financial Services
- Seed, Pre-Seed, Angel
- United Kingdom, United States
Portfolio highlights
- nMachine — A Low-Code solution for creating extraordinary Day 2 Operations platforms - called nMachines - for your existing Kubernetes-based applications, that can be shared inside and outside your organization.
- Incard — Welcome to the world's first payment solution designed exclusively for e-commerce, entrepreneurs, dropshippers and influencers. Join our waitlist now.
- Tuza — Find the right card machine for your business, with good rates and the best features. Search the top providers in minutes, including Worldpay, Barclaycard, Tyl and Teya.
Ed Parkinson
Show more...Investment focus
- Software, Health Care, Life Science
- Seed
- United Kingdom
Portfolio highlights
- Antiverse — Designing biologics for 100 challenging targets
Edward Lando is the founder of Pareto Holdings. He previously worked at Horizons School of Technology as a co-founder. Edward Lando attended the Wharton School.
Show more...Investment focus
- Software, Health Care, Information Technology
- Seed, Pre-Seed, Funding Round
- United States, France, United Kingdom
Portfolio highlights
- Flent — Flent offers fully furnished designer homes.
- Swaive — Swaive operates a financial firm that invests in risk-free instruments. The organization allows you to park your money without risk.
- ToolBelt — The only platform built specifically for licensed pros in residential construction looking for work or finding labor.
Aidan Gomez is based out of Toronto, Ontario and is the co-founder & CEO at Cohere. Aidan Gomez attended the University of Oxford.
Show more...Investment focus
- Artificial Intelligence, Software, Information Technology
- Seed, Pre-Seed, Series A
- United States, United Kingdom, Canada
Portfolio highlights
- Extropic AI — The next era of computing isn't dead. It's alive. More coming soon.
- Helical — The full power of DNA & (m)RNA Bio Foundation Models in one open-core platform. Accelerate Drug Discovery with AI.
- Borderless AI — Borderless AI is an Employer of Record (EOR) & PEO platform simplifying global payroll management & team hiring to empower your growth worldwide. Book a demo now!
Mark is currently a Founding Partner and LP and Investment Committee member at Kindred Capital, a European Seed-Stage Venture fund, based in London. He was a General Partner at Balderton Capital/ Benchmark Europe from 2002 through 2015, and an EIR at Benchmark Capital in 1999/2000.He spent the prior 15 years @ Goldman Sachs, where hewas a General Partner and Management Committee member. He studied Economics at both University of Oxford and Queen's University in Canada.
Show more...Investment focus
- Software, E-Commerce, Health Care
- Series A, Seed, Series C
- United Kingdom, United States, The Netherlands
Portfolio highlights
- 8fit — Get personalized workouts, custom meal plans, and nutrition guidance, right in the palm of your hand. Prioritize progress over perfection with the 8fit app!
- Ufonia — Dora is a clinical AI agent that calls and supports your cataract patients, empowering your ophthalmology practice to scale without compromise on care.
- Arctoris — Arctoris is a platform company headquartered in Oxford, with its US operations based in Boston and its APAC operations based in Singapore. Arctoris developed and operates a unique drug discovery platform powered by advanced robotics and data science combined with an experienced team of biotech & pharma veterans. Arctoris actively pursuesseveral drug discovery programs in oncology and neuro, while also providing access to its platform to select biotech and pharma partners. Arctoris' approach of data-driven drug discovery leads to higher chance of success, and an accelerated progression of programs towards the clinic.
Inaki Berenguer is the President and Co-founder at iPronics Programmable Photonics.
Show more...Investment focus
- FinTech, E-Commerce, Financial Services
- Seed, Angel, Pre-Seed
- Spain, United States, United Kingdom
Portfolio highlights
- Ukio — Artfully designed fully furnished apartments available for extended stays
- Paack — Online sales growth and customer satisfaction are hampered by inadequate delivery experiences. Existing last mile delivery companies are incapable of providing a truly customer-centric approach. Our proprietary technology stack and operational excellence is built specifically to service time slot deliveries, controlled entirely by the endcustomer. This creates unprecedented results through basket conversion, loyalty, repeat purchase, acquisition, brand image and customer satisfaction, plus they can actually help the environment.Paack operates in Europe (UK, France, Spain and Portugal).
- Openlytics — Openlytics is a visual analytics platform. It allows Data Workers to create pipelines for data transformation and analysis, in a visual way. Our mission is to empower everyone in the organization to solve data problems, without waiting for developers.Openlytics is an early-stage company, looking to build a founding team that can shape thedirection of the product. We’re seed-funded, remote-first, and hiring.If you're interested in learning more, email us at hello@openlytics.io.
Gilad Engel
Show more...Investment focus
- Hardware, Analytics, Biotechnology
- Seed, Pre-Seed
- France, Israel, United Kingdom
Portfolio highlights
- Joe — Joe is an financial service that reimburses and allows ALL expenses to be paid in several installments.
- Gardin — We believe in a world in which everyone has the right to access high quality, nutritious food that is good for you and for our planet. Our environmental issues are real, something, somewhere needs to change. Gardin promises to create the step-change required by deploying its technology.
- Fourier Optics — Fourier optics creates meta-surface based optical systems for Augmented Reality glasses
Jon Oringer is the founder and chairman of Shutterstock.
Show more...Investment focus
- Software, Information Technology, Health Care
- Seed, Pre-Seed, Series A
- United States, France, United Kingdom
Portfolio highlights
- SLUSHY — SLUSHY is a secure mobile web based platform for content creators to find, grow, & monetize their audiences. A creator first, tech-driven tool, designed with key discoverability features and audience insights. In a market where existing solutions (OnlyFans, Patreon) fall short of their creators' demands, SLUSHY provides an alternativesolution for professional content creators that prioritizes their monetization, support and management needs. SLUSHY incorporates a powerful legal framework, with robust compliance tools including simplified consent, ID verification, and content moderation. The new home of unrestricted content, SLUSHY is here.
- Skedway — The optimization hub for the Modern Enterprise - Visualize, integrate and manage every shared company asset in one place.
- Unsloth AI — Unsloth is an open-source, no-code web UI for training, running and exporting open models in one unified local interface.
Jim Mellon is an international investor with interests in several industries. After leaving Oxford, where he studied PPE, (Philosophy, Politics and Economics) he worked in Asia and the United States for two fund management companies, GT and Thornton, before establishing his own business in 1991. His business operations include two components, alisted fund management company called Charlemagne Capital, and an Asian mining group, Regent Pacific.In addition, Mr. Mellon is Co-Chairman of West African Minerals Corporation and Regent Pacific Group. He is on the board of a number of public quoted companies, including Brazilian Gold Corporation, Charlemagne Capital Limited, Manx Financial Group, Plethora Solutions, Polo Resources, Port Erin Biophara Investments Limited, and the Speymill plc. He is the life tenant of a trust which owns the Burnbrae Group, which has substantial assets in the biotechnology, financial services, property, mining and leisure sectors. Mr. Mellon spends most of his time working on startup ideas and investing. His book, “Wake Up!” was published in 2005; his second book "10 Investments for the Ten Years Ahead" was published in 2008. In 2012, he co-wrote "Cracking the Code" which focuses on the biotechnology sector and how to profit from it. Mr. Mellon lives in the Isle of Man, Brussels and Ibiza and is an honorary fellow of Oriel College, Oxford.
Show more...Investment focus
- Biotechnology, Food and Beverage, Health Care
- Series A, Seed, Funding Round
- United States, United Kingdom, Germany
Portfolio highlights
- Voxia — Amy collects and analyzes information from all over the web and provides actionable insights about your leads, prospects and clients, all in one click.
- Monaco Foundry — We are a team of Serial Entrepreneurs, former Senior Government Advisors and Fortune 500 Executives. A global venture accelerator that invests in early to mid-stage companies and their growth through a unique sweat equity model.
- The Duppy Share — The Duppy Share Caribbean Rum is the best rum for cocktails, mixed drinks and rum gifts. Try all our rum recipes, from rum and ginger to dark rum punch.
Hugh Grant is President and Chief Executive Officer at Monsanto.
Show more...Investment focus
- Biotechnology, Machine Learning
- Seed, Funding Round
- United Kingdom
Portfolio highlights
- Bactobio — At Bactobio, our mission is to create a safer and greener world by harvesting valuable metabolites from biological dark matter.
Ariel Poler is the Co-Founder of Reveri Health. Ariel is an Internet entrepreneur, mentor, and investor. He was the founder of IPRO, the first web analytics company, and of Topica, one of the first email communities. Ariel was a board member of Kana Software, LinkExchange, Odeo, LOLapps, and StumbleUpon. He currently serves on the boards of FreedomFinancial Network, MixTent, Strava, and Scan Inc. Ariel’s angel investments include AdMob, Flixster, Slideshare, Xobni, RockYou, and Outright, BrightRoll, Instructables, Causes, Kongregate and NexTag. Ariel holds a B.S. in Mathematics with Computer Science from MIT and an MBA from Stanford University. He is originally from Venezuela and lives in San Francisco with his wife and three children.
Show more...Investment focus
- Software, Social Media, Internet
- Seed, Series A, Angel
- United States, Spain, Mexico
Portfolio highlights
- Goin — Goin is a mobile application to save money easily and take advantage of it without knowing how to invest, through Machine Learning algorithms that allow you to accumulate the user's money through small daily gestures. he three Spanish founders, David, Carlos and Gabriel, were looking for a way to optimize their own money, and decided toconduct an experiment by exchanging their debit cards and thus saving 62% during those two months of rehearsal. This is how Goin emerged, which aims to meet the needs of 100% of Millennials, of which 83% confess that they do not know how to save, making available an easy-to-use tool that enhances their finances and lifestyle. On the one hand, the Barcelona startup allows the user to add money automatically and multiply it without having previous knowledge of investment. Goin uses a simple system that first asks to know the user through questions about their habits and, in this way, they are offered automatic systems and methods of saving. Once the user adds money to the app, they can transfer part or all of it to investment, or to their bank account. Its Smart Saving technology manages to accumulate money with small, everyday gestures, such as rounding a payment.
- Kiwibot — Delivery robots to optimize your business and deliver safely and timely to your customers.
- Grin Scooters — Grin Scooters is a software company that operates network of operational shared electric scooters. Currently, Grin only operates in Mexico City, Guadalajara, Monterrey, Sao Paulo and Bogota but it has plans to expand to other cities throughout Latin America.
In 2010, Nick founded Lightsource Renewable Energy, then just a six-person start-up, which quickly grew over 5 years to become Europe’s largest solar developer and operator and a recognised global leader. In his role as Group CEO, Nick’s dynamic leadership and vision has driven the company to tremendous success and in December 2017, Lightsourceannounced a strategic partnership with BP which has committed aggressively to accelerate the low carbon transition. The company has rebranded to Lightsource BP in affirmation of this powerhouse commitment which is set to shape the future of global energy delivery. Nick previously sat at Board and Senior Director level in a number of leading retail financial service companies. Throughout his career, Nick has always been recognised for his entrepreneurial skill and success in pairing retail financial products with low-risk, predictable investments.
Show more...Investment focus
- Biofuel, Agriculture, Artificial Intelligence
- Seed
- United Kingdom
Portfolio highlights
- Better Origin — At Better Origin, our mission is to fix the broken food chain by converting waste into high-value insect products.
- Better Origin — At Better Origin, our mission is to fix the broken food chain by converting waste into high-value insect products.
Mati Staniszewski is the Co-Founder of ElevenLabs.
Show more...Investment focus
- Software, Information Technology, Artificial Intelligence
- Pre-Seed
- United States
Portfolio highlights
- VitVio — VitVio is a platform built around AI and computer vision with the goal of improving efficiency and quality of care in operating rooms.
- SalesPatriot — We deploy AI into supply chains that the West depends on.
- Black Forest Labs — Black Forest Labs creates advanced generative deep learning models for images and videos. They focus on making these technologies widely accessible and transparent, ensuring that their innovations are easy to use and understand. This approach aims to democratize access to cutting-edge technology and foster greater trust and utility.
Patrick Pichette is based out of London, England, and is the Partner of Inovia Capital and also Board Member of Cohere. Patrick Pichette previously worked at Twitter as a Board of Directors. Patrick Pichette attended the University of Oxford.
Show more...Investment focus
- Artificial Intelligence, Software, Machine Learning
- Seed, Series A, Series B
- United Kingdom, Germany, United States
Portfolio highlights
- Kaedim — AI-powered 3D asset creation service delivering fast, production-ready 3D assets. Scale 3D pipelines without hiring, accelerate 3D game art production, and reduce 3D asset costs by up to 90%.
- Apheris — Superior drug discovery models through federated data networks
- made of air — Made of Air is a carbon-negative materials company. They take low-value wood waste and transform it into high-value, carbon-negative thermoplastics. These thermoplastics can be formed with all traditional heat-forming methods and used for a wide variety of applications, turning manufactured goods into engineered carbon sinks.
Robert Kopple
Show more...Investment focus
- FinTech, Finance, Life Science
- Funding Round, Convertible Note
- United States, United Kingdom
Portfolio highlights
- Tradier — Tradier is a financial services cloud provider that offers a groundbreaking solution to serve platform providers, developers and investors. The Tradier solution features an innovative set of fully hosted APIs, modules, and "out of the box" tools that are leveraged by a growing list of providers.
- ILC Therapeutics — ILC Therapeutics Ltd is an early-stage biotechnology company focused on modulating the Innate Immune System through the development of novel peptide therapeutics for the treatment of Covid-19, Cancer, Atopic Dermatitis, and Psoriasis.
Damien Lane has spent the last 20 years investing in private companies, both in Private Equity where he was a partner with Electra Partners, then at Octopus Ventures where he was a senior member of the investment team. Having made a number of angel investments, Damien co-founded Episode 1 with Simon and Adrian in 2012. While at Episode 1,Damien has led investments in Carwow, Scurri, Touch Surgery, Attest and Zipcube and loves working with early stage teams of entrepreneurs; helping them develop their early stage startup into a fast growth enterprises capable of raising more funding from later stage investors. When he is not trying to help businesses to implement an optimal approach to growth, Damien can mostly be found running around Hampstead Heath or the Coastal paths of Great Britain. Having trained obsessively to run a 2:52 Marathon in 2015, he is now trying to dip below 2:50, in the spirit of continuous improvement. Damien has an MBA from Cambridge University and a Masters degree in PE from Oxford University.
Show more...Investment focus
- SaaS, Software, Health Care
- Seed, Pre-Seed, Series A
- United Kingdom, United States, Ireland
Portfolio highlights
- Calira — Calira (formerly Clustermarket). Give researchers an easy way to book equipment, improve equipment utilisation, and get structured lab usage data.
- Realla — Search the entire commercial property market for offices, serviced office space, retail, industrial for sale and to rent
- IVO — Platform to allow media owners to deepen advertiser engagement, increase profitability and commercialise ad solutions with ease.
Jon Oringer is the founder and chairman of Shutterstock.
Show more...Investment focus
- Software, Information Technology, E-Commerce
- Seed, Pre-Seed, Series A
- United States, United Kingdom, France
Portfolio highlights
- SLUSHY — SLUSHY is a secure mobile web based platform for content creators to find, grow, & monetize their audiences. A creator first, tech-driven tool, designed with key discoverability features and audience insights. In a market where existing solutions (OnlyFans, Patreon) fall short of their creators' demands, SLUSHY provides an alternativesolution for professional content creators that prioritizes their monetization, support and management needs. SLUSHY incorporates a powerful legal framework, with robust compliance tools including simplified consent, ID verification, and content moderation. The new home of unrestricted content, SLUSHY is here.
- Unsloth AI — Unsloth is an open-source, no-code web UI for training, running and exporting open models in one unified local interface.
- OneImaging — OneImaging makes life-saving diagnostics affordable, accessible, and personal. We connect employers, health plans, and members to a trusted national network of imaging centers, delivering faster answers with transparent pricing and premium care across MRIs, CT scans, ultrasounds, mammograms, X-rays and more. We serve organizations looking to control medical spend and individuals who need reliable results without delays. Every scan booked through OneImaging is proof that healthcare can be simpler, cheaper, and kinder.
Serge Chiaramonte
Show more...Investment focus
- FinTech, Financial Services, Information Technology
- Seed, Pre-Seed, Funding Round
- United Kingdom, United States, France
Portfolio highlights
- Desia — Desia provides advanced AI applications for productivity, automation, and analytics for financial services.
- qomodo — Qomodo: La piattaforma BNPL innovativa. Rate a tasso zero, approvazioni veloci, transazioni sicure. Rivoluzionaria nell'acquisto per aziende e consumatori.
- Tranched — Introducing real-time on-chain securitisation. Fintech Lenders and Professional Investors can now launch an institutional-grade transaction up to 90% faster than before.
Pratima is a Venture Partner at Nauta Capital and is based in London. At Nauta, Pratima focuses on enterprise software and deep tech domains.Pratima has 18+ years of professional experience. She is a software developer by background and spent several years in Silicon Valley working on developing intelligent network services in the networkmanagement domain. Pratima joins Nauta from US-based cybersecurity-focused investment firm Paladin Capital. Previously, Pratima led investments and acquisitions at Cisco Corporate Development in Europe with a specific focus on ML/AI, Enterprise Collaboration and Silicon. During her investment career, Pratima led an investment or held board seats in Aimotive, Adbrain, Evrythng, Secure Code Warrior, decentriq, Dashbird, and several fund investments. She also managed investments in several companies including Behaviosec, Italtel, ip.access, and Corvil.Pratima received her MBA from INSEAD in France and an MS in computer science from the Virginia Polytechnic Institute and State University in the US. Pratima is a co-author of a US patent in the area of network device clusters and high availability.
Show more...Investment focus
- Analytics, Cyber Security, SaaS
- Seed, Pre-Seed, Series A
- United Kingdom, France, Croatia
Portfolio highlights
- Gardin — We believe in a world in which everyone has the right to access high quality, nutritious food that is good for you and for our planet. Our environmental issues are real, something, somewhere needs to change. Gardin promises to create the step-change required by deploying its technology.
- Mindflow — Mindflow is a No-Code & Agentic Automation & Orchestration Platform that enables all Enterprise Cyber IT Professionals to Automate Mundane tasks and to deploy AI Agents at scale.
- ESPROFILER — ESPROFILER uniquely combines security spend, commercials, and capabilities with threats helping security leaders maximise their investments.
Jon Oringer is the founder and chairman of Shutterstock.
Show more...Investment focus
- Software, Information Technology, Health Care
- Seed, Pre-Seed, Series A
- United States, United Kingdom, France
Portfolio highlights
- ToolBelt — The only platform built specifically for licensed pros in residential construction looking for work or finding labor.
- Scaler — Scaler empowers real estate managers to protect investments, reduce operational costs, and meet reporting obligations. Our best-in-class tech delivers faster decisions, smarter strategies, and audit-ready documentation across your entire real estate portfolio
- OneImaging — OneImaging makes life-saving diagnostics affordable, accessible, and personal. We connect employers, health plans, and members to a trusted national network of imaging centers, delivering faster answers with transparent pricing and premium care across MRIs, CT scans, ultrasounds, mammograms, X-rays and more. We serve organizations looking to control medical spend and individuals who need reliable results without delays. Every scan booked through OneImaging is proof that healthcare can be simpler, cheaper, and kinder.
Nadav Ben-Chanoch
Show more...Investment focus
- Software, Information Technology, Health Care
- Seed, Pre-Seed, Funding Round
- United States, United Kingdom, France
Portfolio highlights
- Swaap — We we build & operate onchain trading systems.
- micro1 — We help companies hire and manage the best software engineers easily.
- Dotfile — Dotfile is the Compliance Orchestration Platform for Fintechs. Streamline KYC & KYB and scale AML/CFT due diligences over +200 countries.
John Anthony Knight
Show more...Investment focus
- Software, Life Science, Biotechnology
- Seed
- United Kingdom
Portfolio highlights
- Synthace — The Synthace Experiment Platform lets you design powerful experiments, run them in your lab, & gather automatically structured datasets. No code necessary.
Jon Moulton is a British venture capitalist. He is the founder and managing partner of the private equity firm Better Capital, and is the former managing partner of the private equity firm Alchemy Partners.
Show more...Investment focus
- Financial Services, FinTech, Banking
- Funding Round, Seed, Series A
- United Kingdom, Cyprus, Luxembourg
Portfolio highlights
- Pockit — Open a prepaid account in 3 minutes online or in-app, get your contactless prepaid card in 2 working days with no credit check.
- Hometree — Keep yourself warm with Hometree, and try our no price hike promise. Compare our different boiler & home cover plans to see how you can save.
- Hellas Direct — Hellas Direct is a digital-first, full-stack insurance company, empowered by cutting-edge technology and artificial intelligence. The Cyprus-based company is backed by a roster of leading investors, including Portag3, IFC (a member of the World Bank), Endeavor Catalyst, former Goldman Sachs economist Lord O’Neill and private equity veteran JonMoulton. Modelling itself on Amazon, Hellas Direct aims to disrupt the insurance value chain by adopting an extreme focus on operational excellence.
Dr. McCamish is President and Chief Executive Officer of IconOVir Bio. Previously he was President and Chief Executive Officer of Forty Seven, Inc. He led Forty Seven, Inc. during critical phases of clinical development to help patients defeat their cancer. This included growing from a valuation of $169 million as a private company through a SeriesB offering, Initial Public Offering, two secondary fund raises and finally the acquisition of Forty Seven by Gilead for $4.9 Billion.He is an international expert in biologic and biosimilars development and manufacturing. Mark is passionate about mentoring and developing people while focusing on meeting patient needs through efficient, commercially viable efforts. He is a senior executive with extensive experience at multiple companies including Abbott, Amgen, and Novartis/Sandoz. He led pioneering efforts in filing/launching biosimilars worldwide. He has demonstrated a commercial mindset in establishing research and development strategies leading to approvals and commercial success in multiple therapeutic areas and regulatory categories including biologics, biosimilars, drugs, devices, and medical foods.He received Bachelor’s and Master’s degrees from UCSB and, after completing his PhD in Human Nutrition from Penn State and MD from UCLA, he completed Residency and Fellowship Training at the University of California, Davis. He held professorships at UC Davis and The Ohio State University
Show more...Investment focus
- Medical, Biopharma, Biotechnology
- Seed
- United Kingdom
Portfolio highlights
- Nemesis Bioscience — Nemesis Bioscience is a UK-based biopharmaceutical company developing products to resurrect anti-microbial therapies made ineffective by increasing microbial resistance. The company develops Nemesis Symbiotics that will make existing antibiotics work again, prevent the spread of resistance genes, and so also protect the efficacy of new antibiotics.The technology is applicable to all antibiotic classes, all known resistance mechanisms and all bacteria.Other applications include reduction of chemotherapeutic toxicity, inactivation of virulence factors, and in vivo synthesis of biofuels and therapeutics.The company was awarded the King’s College, Cambridge Entrepreneurship Award for 2014 and has filed patent applications internationally on its inventions.
Investing in consumer stuff (content, community, commerce, creators). Advisor at Jellysmack, previously Founding Team at The Family
Show more...Investment focus
- Financial Services, FinTech, Software
- Seed, Pre-Seed
- United States, France, United Kingdom
Portfolio highlights
- Figures — Figures delivers reliable, up-to-date salary and equity data, allowing the people professionals to plan and benchmark their compensation plan
- Aria — TELL BEAUTIFUL STORIES
- Intros AI — Intros is a developer of a communication platform to help people communicate within the community. Its platform also allows people to talk with each other through direct messaging or in interest groups and automate introductions between their members. Through this software, users feel more connected and supported while helping communities scaletheir personalized introductions.The company was founded in 2020 and is headquartered in Danvers, Massachusetts.
Rick Bernstein is the Chief Commercial Officer for MedNet responsible for the development of the commercial infrastructure and strategy for MedNet, a healthcare technology company specializing in eClinical solutions for the global life sciences industry. Rick is currently leading the development of an optimized sales, business development, anddistribution strategy to drive aggressive growth across key market segments, including CROs and pharmaceutical, medical device and biotechnology sponsors.
Show more...Investment focus
- Health Care, Biotechnology, Agriculture/Farming
- Seed
- United Kingdom
Portfolio highlights
- Phytoform Labs — Phytoform Labs is improving crops to make agriculture more sustainable and nutritious
Alex Payne the co-founder and CTO of BankSimple, an online banking disruption startup. Previously he was an Engineer at Twitter and led the API team.
Show more...Investment focus
- Food Processing, Data Visualization, Software
- Seed, Series A, Funding Round
- United States, Singapore, United Kingdom
Portfolio highlights
- Shiok Meats — Delicious, healthy & cell-based seafood from Shiok Meats. Get variety of cultivated meat, cultivated seafood, cell cultured meat & Lab Meats in Singapore.
- Extracellular — Extracellular is a scale-up and development partner, channelling biology, digitalisation and biomanufacturing expertise to accelerate the potential of cultivated meat.
- Next Level Burger — Order burgers, shakes, chik'n, fries and more from America's first 100% plant-based burger joint chain. All organic veggies, always non-GMO. Vegan menu options for all!
Sharaf Yamani - Managing Director @ Windlesham Advisors
Show more...Investment focus
- Biotechnology, Software, Life Science
- Seed
- India, United Kingdom
Portfolio highlights
- CyGenica — CyGenica uses a non-viral, non-toxic platform to develop in vitro and in vivo delivery solutions for drugs, gene editing components, and antibiotics.
- Synthace — The Synthace Experiment Platform lets you design powerful experiments, run them in your lab, & gather automatically structured datasets. No code necessary.
Christine Soden is the Non-Executive Director at Arecor.
Show more...Investment focus
- Education, Health Care, Biotechnology
- Funding Round, Post-IPO Equity
- United Kingdom
Portfolio highlights
- Arecor — Arecor is a leader in developing superior biopharmaceuticals through the application of its innovative formulation technology platform. Arecor is leveraging this platform to develop a portfolio of proprietary products enabling improved treatments for diabetes care via the innovative reformulation of approved proteins and peptides.In addition toits internal product portfolio, Arecor partners with leading pharmaceutical and biotech companies to deliver superior reformulations of their proprietary products, which would otherwise not be possible using conventional formulation science.
Sarah Howell joined Arecor Limited as Chief Executive Officer in 2015.
Show more...Investment focus
- Education, Health Care, Biotechnology
- Funding Round, Post-IPO Equity
- United Kingdom
Portfolio highlights
- Arecor — Arecor is a leader in developing superior biopharmaceuticals through the application of its innovative formulation technology platform. Arecor is leveraging this platform to develop a portfolio of proprietary products enabling improved treatments for diabetes care via the innovative reformulation of approved proteins and peptides.In addition toits internal product portfolio, Arecor partners with leading pharmaceutical and biotech companies to deliver superior reformulations of their proprietary products, which would otherwise not be possible using conventional formulation science.
Sami Mikati is a Director of Synthace Ltd. Investor and commercial executive with deep experience and network across energy and engineering industries in Europe, the Middle East and Africa.
Show more...Investment focus
- Biotechnology, Software, Life Science
- Seed
- India, United Kingdom
Portfolio highlights
- CyGenica — CyGenica uses a non-viral, non-toxic platform to develop in vitro and in vivo delivery solutions for drugs, gene editing components, and antibiotics.
- Synthace — The Synthace Experiment Platform lets you design powerful experiments, run them in your lab, & gather automatically structured datasets. No code necessary.
Oliver is Head of Life Sciences at Future Planet Capital and manages investments from the UK Innovation and Science Seed Fund. He has invested in HC, ag tech, clean tech and AI businesses and sits on the board on a number of biotech companies. Prior to joining FPC, Oliver managed commercialisation of early stage HC technologies at ImperialInnovations/Touchstone and has previously managed licensing at Ark Therapeutics as well as various HC consultancy roles. He also manged a team of buy side analysts at Instinet. Oliver has an MSc from the University of Bristol and his PhD research was at the University of Nottingham.
Show more...Investment focus
- Biotechnology, Health Care, AgTech
- Seed, Pre-Seed, Funding Round
- United Kingdom
Portfolio highlights
- twig bio — twig bio operates as a bioengineering startup. twig bio using AI and robotics to find sustainable replacements for harmful ingredients.
- Solasta Bio — Solasta Bio develops environment-friendly products that meet a global need for new and effective crop protection.
- Resurrect Bio — Resurrect Bio is a plant biotechnology company that will improve the immune systems of crop species to revolutionize the agricultural industry.
Jim started work at Analysys Limited, a Cambridge-based telecommunications consultancy, heading up its IT, software and web development initiatives. Jim then joined Abcam as a Technical Director, and took over the operational management of the UK office as Managing Director in June 2004, working on both cost saving and efficiency improvementprojects. In 2009, Jim became Chief Operating Officer, with the responsibility for overseeing the operational strategy of the Group. Jim is a Director of Chesterton Community College, Chesterton Sports Centre Limited and Cambridge Nutraceuticals Limited. He has also taken up a non-executive position at Quartix Holdings Plc. Jim had over 15 years’ experience in developing and implementing IT systems and strategy before moving into a broader operational management role within Abcam.Here his skills have been particularly focused on developing a scalable operating model for Abcam which, supported by IT systems, has underpinned Abcam’s rapid growth over the past decade.
Show more...Investment focus
- Life Science, Biotechnology
- Seed
- United Kingdom
Portfolio highlights
- Qkine — Growth Factors made for stem cells Animal-free We control every step of protein manufacture ensuring all our products are completely animal-free Total transparency Stringent purity and bioactivity testing data for all proteins - know what you are giving your cells Protein innovation Our R&D team
Siddhant Jayakumar
Show more...Investment focus
- Biotechnology, Public Safety, Artificial Intelligence
- Pre-Seed
- United Kingdom
Portfolio highlights
- sable bio — We provide comprehensive, quantified, and flexible Target Safety Intelligence to assist toxicologists, informaticians, and drug discovery scientists in delivering safe and effective new treatments.
Andrew Richards is an established biotechnology entrepreneur and investor with extensive experience from the UK biotechnology sector in research, drug development, commercial deals and scale-up of companies.
Show more...Investment focus
- Biopharma, Education, Biotechnology
- Funding Round, Post-IPO Equity
- United Kingdom
Portfolio highlights
- Arecor — Arecor is a leader in developing superior biopharmaceuticals through the application of its innovative formulation technology platform. Arecor is leveraging this platform to develop a portfolio of proprietary products enabling improved treatments for diabetes care via the innovative reformulation of approved proteins and peptides.In addition toits internal product portfolio, Arecor partners with leading pharmaceutical and biotech companies to deliver superior reformulations of their proprietary products, which would otherwise not be possible using conventional formulation science.
Contact investors today
Find who invests in your industry, stage, and country in 5 minutes.
Find investors — It's Free!